The University of Chicago Header Logo

Andrzej Jakubowiak

TitleProfessor
InstitutionUniversity of Chicago
DepartmentMedicine-Hematology and Oncology
AddressChicago IL 60637
Email
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Nooka AK, Kaufman JL, Rodriguez C, Jakubowiak A, Efebera Y, Reeves B, Wildes TM, Holstein SA, Anderson LD, Badros A, Shune L, Chari A, Pei H, Cortoos A, Patel S, Lin TS, Voorhees PM, Usmani SZ, Richardson PG. Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study. Br J Haematol. 2024 Mar 19. PMID: 38504552.
      Citations:    Fields:    
    2. Derman BA, Zonder J, Reece D, Cole C, Berdeja J, Stefka AT, Major A, Kin A, Griffith K, Jasielec J, Jakubowiak AJ. Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma. Blood Adv. 2023 10 10; 7(19):5703-5712. PMID: 36763537; PMCID: PMC10539870.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    3. Bahlis NJ, Costello CL, Raje NS, Levy MY, Dholaria B, Solh M, Tomasson MH, Damore MA, Jiang S, Basu C, Skoura A, Chan EM, Trudel S, Jakubowiak A, Gasparetto C, Chu MP, Dalovisio A, Sebag M, Lesokhin AM. Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. Nat Med. 2023 10; 29(10):2570-2576. PMID: 37783970; PMCID: PMC10579053.
      Citations: 5     Fields:    Translation:HumansCellsCTClinical Trials
    4. Rojek AE, Kline JP, Feinberg N, Appelbaum DE, Pu Y, Derman BA, Jakubowiak A, Kosuri S, Liu H, Nawas MT, Smith SM, Bishop MR, Riedell PA. Optimization of Metabolic Tumor Volume as a Prognostic Marker in CAR T-Cell Therapy for Aggressive Large B-cell NHL. Clin Lymphoma Myeloma Leuk. 2024 02; 24(2):83-93. PMID: 37827881.
      Citations:    Fields:    Translation:Humans
    5. Voorhees PM, Sborov DW, Laubach J, Kaufman JL, Reeves B, Rodriguez C, Chari A, Silbermann R, Costa LJ, Anderson LD, Nathwani N, Shah N, Bumma N, Efebera YA, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Dinner S, Pei H, Cortoos A, Patel S, Lin TS, Usmani SZ, Richardson PG. Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol. 2023 Oct; 10(10):e825-e837. PMID: 37708911.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    6. Kubicki T, Dytfeld D, Wróbel T, Jamroziak K, Robak P, Czyz J, Tyczynska A, Druzd-Sitek A, Giannopoulos K, Szczepaniak T, Lojko-Dankowska A, Matuszak M, Gil L, Pula B, Rybka J, Majcherek M, Usnarska-Zubkiewicz L, Szukalski L, Zaucha JM, Mikulski D, Czabak O, Lahoud OB, Stefka A, Derman BA, Jakubowiak AJ. Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial. Br J Haematol. 2023 12; 203(5):792-802. PMID: 37691005.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    7. Kubicki T, Derman BA, Dytfeld D, Jakubowiak AJ. Measurable residual disease in peripheral blood in myeloma: dream or reality. Curr Opin Oncol. 2023 11 01; 35(6):574-580. PMID: 37621165.
      Citations:    Fields:    
    8. Mateos MV, Weisel K, Martin T, Jakubowiak A, Stewart AK, Jagannath S, Lin Y, Diels J, Ghilotti F, Thilakarathne P, Perualila NJ, Cabrieto J, Haefliger B, Erler-Yates N, Hague C, Jackson CC, Schecter JM, Strulev V, Nesheiwat T, Pacaud L, Moreau P, Berdeja JG, Einsele H. Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice. Haematologica. 2023 08 01; 108(8):2192-2204. PMID: 36546453; PMCID: PMC10388260.
      Citations: 5     Fields:    Translation:Humans
    9. Palmer S, Lin Y, Martin TG, Jagannath S, Jakubowiak A, Usmani SZ, Buyukkaramikli N, Phelps H, Slowik R, Pan F, Valluri S, Pacaud L, Jackson G. Extrapolation of Survival Data Using a Bayesian Approach: A Case Study Leveraging External Data from Cilta-Cel Therapy in Multiple Myeloma. Oncol Ther. 2023 Sep; 11(3):313-326. PMID: 37270762; PMCID: PMC10447673.
      Citations:    
    10. Frigault MJ, Bishop MR, Rosenblatt J, O'Donnell EK, Raje N, Cook D, Yee AJ, Logan E, Avigan DE, Jakubowiak A, Shaw K, Daley H, Nikiforow S, Griffin F, Cornwell C, Shen A, Heery C, Maus MV. Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma. Blood Adv. 2023 03 14; 7(5):768-777. PMID: 35468618; PMCID: PMC9989524.
      Citations: 12     Fields:    Translation:HumansCellsCTClinical Trials
    11. Nooka AK, Kaufman JL, Rodriguez C, Jakubowiak A, Efebera Y, Wildes T, Holstein SA, Anderson LD, Badros A, Shune L, Chari A, Pei H, Cortoos A, Patel S, Lin TS, Richardson PG, Voorhees P, Reeves B. A plain language summary of daratumumab plus lenalidomide/bortezomib/dexamethasone in transplant-eligible Black patients with newly diagnosed multiple myeloma in the GRIFFIN study. Future Oncol. 2022 Dec; 18(40):4443-4456. PMID: 36799429.
      Citations:    Fields:    Translation:Humans
    12. Derman BA, Chari A, Zonder J, Major A, Stefka AT, Jiang K, Karrison T, Jasielec J, Jakubowiak A. A phase I study of selinexor combined with weekly carfilzomib and dexamethasone in relapsed/refractory multiple myeloma. Eur J Haematol. 2023 May; 110(5):564-570. PMID: 36726221.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    13. Dytfeld D, Jamroziak K, Kubicki T, Robak P, Walter-Croneck A, Czyz J, Tyczynska A, Druzd-Sitek A, Giannopoulos K, Nowicki A, Szczepaniak T, Lojko-Dankowska A, Matuszak M, Gil L, Pula B, Rybka J, Majcherek M, Usnarska-Zubkiewicz L, Szukalski L, Konska A, Zaucha JM, Walewski J, Mikulski D, Czabak O, Robak T, Lahoud OB, Zonder JA, Griffith K, Stefka A, Major A, Derman BA, Jakubowiak AJ, Wróbel T. Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023 02; 24(2):139-150. PMID: 36642080; PMCID: PMC10337122.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    14. Chhabra S, Callander N, Watts NL, Costa LJ, Thapa B, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, Chari A, Silbermann R, Anderson LD, Bal S, Dhakal B, Nathwani N, Shah N, Medvedova E, Bumma N, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Schmidt T, Orlowski RZ, Shain KH, Cowan AJ, Dholaria B, Cornell RF, Jerkins JH, Pei H, Cortoos A, Patel S, Lin TS, Usmani SZ, Richardson PG, Voorhees PM. Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials. Transplant Cell Ther. 2023 03; 29(3):174.e1-174.e10. PMID: 36494017.
      Citations: 6     Fields:    Translation:Humans
    15. Sklavenitis-Pistofidis R, Aranha MP, Redd RA, Baginska J, Haradhvala NJ, Hallisey M, Dutta AK, Savell A, Varmeh S, Heilpern-Mallory D, Ujwary S, Zavidij O, Aguet F, Su NK, Lightbody ED, Bustoros M, Tahri S, Mouhieddine TH, Wu T, Flechon L, Anand S, Rosenblatt JM, Zonder J, Vredenburgh JJ, Boruchov A, Bhutani M, Usmani SZ, Matous J, Yee AJ, Jakubowiak A, Laubach J, Manier S, Nadeem O, Richardson P, Badros AZ, Trippa L, Getz G, Ghobrial IM, Mateos MV. Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma. Cancer Cell. 2022 11 14; 40(11):1358-1373.e8. PMID: 36379208; PMCID: PMC10019228.
      Citations: 7     Fields:    Translation:Humans
    16. Wang B, Derman BA, Langerman SS, Johnson J, Zhang W, Jakubowiak A, Chiu BC. Body Mass Index and Overall Survival of Patients with Newly Diagnosed Multiple Myeloma. Cancers (Basel). 2022 Oct 29; 14(21). PMID: 36358748; PMCID: PMC9657446.
      Citations: 1     
    17. Cohen AD, Hari P, Htut M, Berdeja JG, Usmani SZ, Madduri D, Olyslager Y, Goldberg JD, Schecter JM, Jackson CC, Gries KS, Fastenau JM, Valluri S, Deraedt W, Akram M, Crawford R, Morrison R, Doward L, Morgan K, Seldam ST, Jakubowiak A, Jagannath S. Patient Perceptions Regarding Ciltacabtagene Autoleucel Treatment: Qualitative Evidence From Interviews With Patients With Relapsed/Refractory Multiple Myeloma in the CARTITUDE-1 Study. Clin Lymphoma Myeloma Leuk. 2023 01; 23(1):68-77. PMID: 36357295.
      Citations: 3     Fields:    Translation:Humans
    18. Martin T, Lin Y, Agha M, Cohen AD, Htut M, Stewart AK, Hari P, Berdeja JG, Usmani SZ, Yeh TM, Olyslager Y, Goldberg JD, Schecter JM, Madduri D, Jackson CC, Deraedt W, Gries KS, Fastenau JM, Trudeau JJ, Akram M, Pacaud L, Jakubowiak A, Jagannath S. Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study. Lancet Haematol. 2022 Dec; 9(12):e897-e905. PMID: 36215989.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    19. Derman BA, Kansagra A, Zonder J, Stefka AT, Grinblatt DL, Anderson LD, Gurbuxani S, Narula S, Rayani S, Major A, Kin A, Jiang K, Karrison T, Jasielec J, Jakubowiak AJ. Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study. JAMA Oncol. 2022 09 01; 8(9):1278-1286. PMID: 35862034; PMCID: PMC9305600.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    20. Chiu BC, Zhang Z, Derman BA, Karpus J, Luo L, Zhang S, Langerman SS, Sukhanova M, Bhatti P, Jakubowiak A, He C, Zhang W. Genome-wide profiling of 5-hydroxymethylcytosines in circulating cell-free DNA reveals population-specific pathways in the development of multiple myeloma. J Hematol Oncol. 2022 08 16; 15(1):106. PMID: 35974364; PMCID: PMC9380317.
      Citations: 3     Fields:    Translation:Humans
    21. Major A, Jakubowiak A, Derman B. Longitudinal Real-World Neuropathy and Patient-Reported Outcomes With Bortezomib and Lenalidomide in Newly Diagnosed Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2022 11; 22(11):e1000-e1008. PMID: 35922273.
      Citations: 1     Fields:    Translation:Humans
    22. Derman BA, Jakubowiak AJ, Thompson MA. Clinician survey regarding measurable residual disease-guided decision-making in multiple myeloma. Blood Cancer J. 2022 07 11; 12(7):108. PMID: 35821020; PMCID: PMC9276661.
      Citations:    Fields:    Translation:Humans
    23. Jakubowiak AJ, Kumar S, Medhekar R, Pei H, Lefebvre P, Kaila S, He J, Cortoos A, Londhe A, Mavros P, Lin TS, Usmani SZ, Lafeuille MH. Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma. Oncologist. 2022 07 05; 27(7):e589-e596. PMID: 35462406; PMCID: PMC9256027.
      Citations: 4     Fields:    Translation:Humans
    24. Martin T, Usmani SZ, Berdeja JG, Agha M, Cohen AD, Hari P, Avigan D, Deol A, Htut M, Lesokhin A, Munshi NC, O'Donnell E, Stewart AK, Schecter JM, Goldberg JD, Jackson CC, Yeh TM, Banerjee A, Allred A, Zudaire E, Deraedt W, Olyslager Y, Zhou C, Pacaud L, Madduri D, Jakubowiak A, Lin Y, Jagannath S. Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. J Clin Oncol. 2023 02 20; 41(6):1265-1274. PMID: 35658469; PMCID: PMC9937098.
      Citations: 93     Fields:    Translation:Humans
    25. Rouhani SJ, Yu J, Olson D, Zha Y, Pezeshk A, Cabanov A, Pyzer AR, Trujillo J, Derman BA, O'Donnell P, Jakubowiak A, Kindler HL, Bestvina C, Gajewski TF. Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies. J Immunother Cancer. 2022 06; 10(6). PMID: 35732350; PMCID: PMC9226983.
      Citations: 6     Fields:    Translation:HumansCellsPHPublic Health
    26. Landgren O, Kazandjian D, Roussel M, Jasielec J, Dytfeld D, Anderson A, Kervin TA, Iskander K, McFadden I, Jakubowiak AJ. Efficacy and safety of carfilzomib-lenalidomide-dexamethasone in newly diagnosed multiple myeloma: pooled analysis of four single-arm studies. Leuk Lymphoma. 2022 10; 63(10):2413-2421. PMID: 35549810.
      Citations: 2     Fields:    Translation:Humans
    27. Nooka AK, Kaufman JL, Rodriguez C, Jakubowiak A, Efebera Y, Reeves B, Wildes T, Holstein SA, Anderson LD, Badros A, Shune L, Chari A, Pei H, Cortoos A, Patel S, Bartlett JB, Vermeulen J, Lin TS, Richardson PG, Voorhees P. Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN. Blood Cancer J. 2022 04 13; 12(4):63. PMID: 35418120; PMCID: PMC9007985.
      Citations: 3     Fields:    Translation:Humans
    28. Cohen AD, Parekh S, Santomasso BD, van de Donk NWCJ, Lendvai N, Jackson CC, De Braganca KC, Schecter JM, Marquez L, Lee E, Cornax I, Zudaire E, Li C, Olyslager Y, Madduri D, Varsos H, Pacaud L, Akram M, Geng D, Jakubowiak A, Jagannath S, Gállego Pérez-Larraya J, Arnulf B, Mateos MV, Einsele H. Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer J. 2022 02 24; 12(2):32. PMID: 35210399; PMCID: PMC8873238.
      Citations: 37     Fields:    Translation:Humans
    29. Kumar S, Dimopoulos MA, Facon T, Jakubowiak A, Usmani SZ, Cook G, Quach H, Ukropec J, Ramaswami P, Pei H, Qi M, Sun S, Wang J, Krevvata M, DeAngelis N, Heuck C, Van Rampelbergh R, Kudva A, Kobos R, Qi M, Bahlis NJ, San-Miguel J, Avet-Loiseau H, Paiva B, Mateos MV, Touzeau C, Cavo M. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE. Blood. 2022 01 27; 139(4):492-501. PMID: 34269818; PMCID: PMC8796656.
      Citations: 35     Fields:    Translation:HumansCTClinical Trials
    30. Usmani SZ, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D, Weisel K, Gavriatopoulou M, Rabin N, Nooka A, Qi M, Beksac M, Jakubowiak A, Ding B, Zahlten-Kumeli A, Yusuf A, Dimopoulos M, Oriol A. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. Lancet Oncol. 2022 01; 23(1):65-76. PMID: 34871550.
      Citations: 43     Fields:    Translation:HumansCTClinical Trials
    31. Costa LJ, Davies FE, Monohan GP, Kovacsovics T, Burwick N, Jakubowiak A, Kaufman JL, Hong WJ, Dail M, Salem AH, Yang X, Masud AA, Munasinghe W, Ross JA, Bueno OF, Kumar SK, Stadtmauer EA. Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma. Blood Adv. 2021 10 12; 5(19):3748-3759. PMID: 34470049; PMCID: PMC8679663.
      Citations: 30     Fields:    Translation:HumansCTClinical Trials
    32. Derman BA, Kosuri S, Jakubowiak A. Knowing the unknowns in high risk multiple myeloma. Blood Rev. 2022 01; 51:100887. PMID: 34479756.
      Citations: 3     Fields:    Translation:Humans
    33. Voorhees PM, Jakubowiak AJ, Kumar SK, Kanapuru B, Baines AC, Bhatnagar V, Ershler R, Theoret MR, Gormley NJ, Pazdur R. Perspectives on Drug Development in Multiple Myeloma-Looking Forward to 2025. Clin Cancer Res. 2022 01 01; 28(1):23-26. PMID: 34315721.
      Citations: 1     Fields:    Translation:Humans
    34. Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, Stewart AK, Hari P, Htut M, Lesokhin A, Deol A, Munshi NC, O'Donnell E, Avigan D, Singh I, Zudaire E, Yeh TM, Allred AJ, Olyslager Y, Banerjee A, Jackson CC, Goldberg JD, Schecter JM, Deraedt W, Zhuang SH, Infante J, Geng D, Wu X, Carrasco-Alfonso MJ, Akram M, Hossain F, Rizvi S, Fan F, Lin Y, Martin T, Jagannath S. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021 07 24; 398(10297):314-324. PMID: 34175021.
      Citations: 395     Fields:    Translation:HumansCTClinical Trials
    35. Jakubowiak A, Usmani SZ, Krishnan A, Lonial S, Comenzo RL, Wang J, de Boer C, Deraedt W, Weiss BM, Schecter JM, Chari A. Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2021 10; 21(10):701-710. PMID: 34274290.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    36. Dimopoulos MA, Suzuki K, Jakubowiak A, Lucio P, Nagy Z, Usenko G, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Losava G, Fujisaki T, Garg M, Wang J, Wroblewski S, Kudva A, Gries KS, Fastenau J, Cavo M, Knop S, Mateos MV, Doyen C, San-Miguel J. Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial. BMC Cancer. 2021 Jun 02; 21(1):659. PMID: 34078314; PMCID: PMC8170980.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    37. Lonial S, Nooka AK, Thulasi P, Badros AZ, Jeng BH, Callander NS, Potter HA, Sborov D, Zaugg BE, Popat R, Degli Esposti S, Byrne J, Opalinska J, Baron J, Piontek T, Gupta I, Dana R, Farooq AV, Colby K, Jakubowiak A. Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM). Blood Cancer J. 2021 05 26; 11(5):103. PMID: 34039952; PMCID: PMC8155129.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    38. Derman BA, Stefka AT, Jiang K, McIver A, Kubicki T, Jasielec JK, Jakubowiak AJ. Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation. Blood Cancer J. 2021 02 05; 11(2):19. PMID: 33563912; PMCID: PMC7873068.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    39. Riedell PA, Wu M, Collins JM, Gideon JM, Jakubowiak AJ, Kline JP, Kosuri S, Liu H, Smith SM, Bishop MR. Bloodless chimeric antigen receptor (CAR) T-cell therapy in Jehovah's Witnesses. Leuk Lymphoma. 2021 06; 62(6):1497-1501. PMID: 33535838.
      Citations:    Fields:    Translation:Humans
    40. Landgren O, Siegel D, Kazandjian D, Costa L, Jakubowiak A. Treatments for newly diagnosed multiple myeloma: when endurance is interrupted. Lancet Oncol. 2020 12; 21(12):e540. PMID: 33271097.
      Citations: 4     Fields:    Translation:Humans
    41. Farooq AV, Degli Esposti S, Popat R, Thulasi P, Lonial S, Nooka AK, Jakubowiak A, Sborov D, Zaugg BE, Badros AZ, Jeng BH, Callander NS, Opalinska J, Baron J, Piontek T, Byrne J, Gupta I, Colby K. Correction to: Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study. Ophthalmol Ther. 2020 Dec; 9(4):913-915. PMID: 32920777; PMCID: PMC7708532.
      Citations: 1     
    42. Jasielec JK, Kubicki T, Raje N, Vij R, Reece D, Berdeja J, Derman BA, Rosenbaum CA, Richardson P, Gurbuxani S, Major S, Wolfe B, Stefka AT, Stephens L, Tinari KM, Hycner T, Rojek AE, Dytfeld D, Griffith KA, Zimmerman TM, Jakubowiak AJ. Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma. Blood. 2020 11 26; 136(22):2513-2523. PMID: 32735641; PMCID: PMC7714092.
      Citations: 25     Fields:    Translation:HumansCTClinical Trials
    43. Derman BA, Langerman SS, Maric M, Jakubowiak A, Zhang W, Chiu BC. Sex differences in outcomes in multiple myeloma. Br J Haematol. 2021 02; 192(3):e66-e69. PMID: 33216365; PMCID: PMC8182969.
      Citations: 6     Fields:    Translation:Humans
    44. Derman BA, Kordas K, Molloy E, Chow S, Dale W, Jakubowiak AJ, Jasielec J, Kline JP, Kosuri S, Lee SM, Liu H, Riedell PA, Smith SM, Bishop MR, Artz AS. Recommendations and outcomes from a geriatric assessment guided multidisciplinary clinic prior to autologous stem cell transplant in older patients. J Geriatr Oncol. 2021 05; 12(4):585-591. PMID: 33162369.
      Citations: 5     Fields:    Translation:Humans
    45. Voorhees PM, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, Chari A, Silbermann R, Costa LJ, Anderson LD, Nathwani N, Shah N, Efebera YA, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Murphy S, Lutska Y, Pei H, Ukropec J, Vermeulen J, de Boer C, Hoehn D, Lin TS, Richardson PG. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020 08 20; 136(8):936-945. PMID: 32325490; PMCID: PMC7441167.
      Citations: 227     Fields:    Translation:HumansCTClinical Trials
    46. Costa LJ, Derman BA, Bal S, Sidana S, Chhabra S, Silbermann R, Ye JC, Cook G, Cornell RF, Holstein SA, Shi Q, Omel J, Callander NS, Chng WJ, Maiolino A, Stadtmauer E, Giralt S, Pasquini M, Jakubowiak AJ, Morgan GJ, Krishnan A, Jackson GH, Mateos MV, Dimopoulos MA, Facon T, Spencer A, Miguel JS, Hari P, Usmani SZ, McCarthy P, Kumar S, Gay F, Paiva B, Hungria V, Mohty M, Manier S. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials. Leukemia. 2021 01; 35(1):18-30. PMID: 32778736.
      Citations: 37     Fields:    Translation:HumansCellsPHPublic Health
    47. Derman BA, Jasielec J, Langerman SS, Zhang W, Jakubowiak AJ, Chiu BC. Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysis. Blood Cancer J. 2020 08 07; 10(8):80. PMID: 32770051; PMCID: PMC7414120.
      Citations: 17     Fields:    Translation:Humans
    48. Farooq AV, Degli Esposti S, Popat R, Thulasi P, Lonial S, Nooka AK, Jakubowiak A, Sborov D, Zaugg BE, Badros AZ, Jeng BH, Callander NS, Opalinska J, Baron J, Piontek T, Byrne J, Gupta I, Colby K. Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study. Ophthalmol Ther. 2020 Dec; 9(4):889-911. PMID: 32712806; PMCID: PMC7708586.
      Citations: 61     
    49. Derman BA, Jasielec JK, Jakubowiak AJ. Clinician attitudes and practices toward measurable residual disease in multiple myeloma. Br J Haematol. 2020 08; 190(3):470-472. PMID: 32506429.
      Citations: 1     Fields:    Translation:Humans
    50. Virani A, Schlei Z, Gleason C, Ackermann M, Wolfe B, Major S, McIver A, Jakubowiak AJ, Jasielec J, Parsad S. Impact of an Oncology Clinical Pharmacist Specialist in an Outpatient Multiple Myeloma Clinic. Clin Lymphoma Myeloma Leuk. 2020 09; 20(9):e543-e546. PMID: 32605900.
      Citations: 1     Fields:    Translation:Humans
    51. Dimopoulos MA, Jakubowiak A, Deraedt W, Lam A, Kampfenkel T, Qi M, He J, Cavo M, San-Miguel J, Mateos MV. Comparative Efficacy of Bortezomib, Melphalan, and Prednisone (VMP) With or Without Daratumumab Versus VMP Alone in the Treatment of Newly Diagnosed Multiple Myeloma: Propensity Score Matching of ALCYONE and VISTA Phase III Studies. Clin Lymphoma Myeloma Leuk. 2020 07; 20(7):480-489. PMID: 32278674.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    52. Chari A, Vogl DT, Jagannath S, Jasielec J, Unger TJ, DeCastro A, Shah J, Kauffman M, Shacham S, Jakubowiak A. Selinexor-based regimens for the treatment of myeloma refractory to chimeric antigen receptor T cell therapy. Br J Haematol. 2020 05; 189(4):e126-e130. PMID: 32124443.
      Citations: 8     Fields:    Translation:Humans
    53. Gavriatopoulou M, Chari A, Chen C, Bahlis N, Vogl DT, Jakubowiak A, Dingli D, Cornell RF, Hofmeister CC, Siegel D, Berdeja JG, Reece D, White D, Lentzsch S, Gasparetto C, Huff CA, Jagannath S, Baz R, Nooka AK, Richter J, Abonour R, Parker TL, Yee AJ, Moreau P, Lonial S, Tuchman S, Weisel KC, Unger TJ, Li K, Chai Y, Li L, Shah J, Shacham S, Kauffman MG, Dimopoulos MA, Mohty M, Choquet S. Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. Leukemia. 2020 09; 34(9):2430-2440. PMID: 32094461; PMCID: PMC7449872.
      Citations: 25     Fields:    Translation:Humans
    54. Xu XS, Moreau P, Usmani SZ, Lonial S, Jakubowiak A, Krishnan A, Luo M, Sun YN, Zhou H, Nnane I, Deraedt W, Qi M, Ukropec J, Clemens PL, Oriol A, Bladé J. Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses. Adv Ther. 2020 04; 37(4):1464-1478. PMID: 32078124; PMCID: PMC7140755.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    55. Dimopoulos MA, Jakubowiak AJ, McCarthy PL, Orlowski RZ, Attal M, Goldschmidt H, Weisel KC, Ramasamy K, Zweegman S, Spencer A, Huang JSY, Lu J, Sunami K, Iida S, Chng WJ, Holstein SA, Rocci A, Skacel T, Labotka R, Palumbo A, Anderson KC, Bladé J. Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma. Blood Cancer J. 2020 02 13; 10(2):17. PMID: 32054831; PMCID: PMC7018731.
      Citations: 41     Fields:    Translation:Humans
    56. Vij R, Nath R, Afar DEH, Raab MS, Guenther A, Jakubowiak AJ, Weisel K, Wong S, Gulbranson S, Sheridan JP, Reddy A, Paiva B, Singhal A, Mateos MV, Berdeja JG, Martínez-López J, Leleu X, San-Miguel JF, Moreau P. First-in-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma. Clin Cancer Res. 2020 05 15; 26(10):2308-2317. PMID: 31969330.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    57. Derman BA, Zha Y, Zimmerman TM, Malloy R, Jakubowiak A, Bishop MR, Kline J. Regulatory T-cell depletion in the setting of autologous stem cell transplantation for multiple myeloma: pilot study. J Immunother Cancer. 2020 01; 8(1). PMID: 31940591; PMCID: PMC7057425.
      Citations: 7     Fields:    Translation:HumansCells
    58. Dimopoulos MA, Suzuki K, Jakubowiak A, Lucio P, Nagy Z, Pour L, Cook M, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Iosava G, Fujisaki T, Garg M, Krevvata M, Chen Y, Wang J, Kudva A, Ukropec J, Wroblewski S, Qi M, Kobos R, Mateos MV, Cavo M, Blade J, Knop S, Doyen C, Grosicki S, Crepaldi A, San-Miguel J. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet. 2020 01 11; 395(10218):132-141. PMID: 31836199.
      Citations: 149     Fields:    Translation:HumansCTClinical Trials
    59. Derman BA, Kordas K, Ridgeway J, Chow S, Dale W, Lee SM, Aguada E, Jakubowiak AJ, Jasielec J, Kline J, Kosuri S, Larson RA, Liu H, Mortel M, Odenike O, Pisano J, Riedell P, Stock W, Bishop MR, Artz AS. Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults. Blood Adv. 2019 11 26; 3(22):3488-3498. PMID: 31725894; PMCID: PMC6880895.
      Citations: 22     Fields:    Translation:Humans
    60. Stefka AT, Johnson D, Rosebeck S, Park JH, Nakamura Y, Jakubowiak AJ. Potent anti-myeloma activity of the TOPK inhibitor OTS514 in pre-clinical models. Cancer Med. 2020 01; 9(1):324-334. PMID: 31714026; PMCID: PMC6943155.
      Citations: 11     Fields:    Translation:HumansAnimalsCells
    61. Hari P, Matous JV, Voorhees PM, Shain KH, Obreja M, Frye J, Fujii H, Jakubowiak AJ, Rossi D, Sonneveld P. Oprozomib in patients with newly diagnosed multiple myeloma. Blood Cancer J. 2019 08 16; 9(9):66. PMID: 31420532; PMCID: PMC6697695.
      Citations: 9     Fields:    Translation:Humans
    62. Landgren O, Sonneveld P, Jakubowiak A, Mohty M, Iskander KS, Mezzi K, Siegel DS. Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma. Leukemia. 2019 09; 33(9):2127-2143. PMID: 31341235; PMCID: PMC6756042.
      Citations: 23     Fields:    Translation:Humans
    63. Ghobrial IM, Vij R, Siegel D, Badros A, Kaufman J, Raje N, Jakubowiak A, Savona MR, Obreja M, Berdeja JG. A Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenström Macroglobulinemia. Clin Cancer Res. 2019 08 15; 25(16):4907-4916. PMID: 31142508.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    64. Jakubowiak AJ, Jasielec JK, Rosenbaum CA, Cole CE, Chari A, Mikhael J, Nam J, McIver A, Severson E, Stephens LA, Tinari K, Rosebeck S, Zimmerman TM, Hycner T, Turowski A, Karrison T, Zonder JA. Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma. Br J Haematol. 2019 08; 186(4):549-560. PMID: 31124580; PMCID: PMC6772147.
      Citations: 29     Fields:    Translation:HumansCTClinical Trials
    65. Chari A, Pineiro L, Jakubowiak A, de Boer C, Wang J, Clemens PL, Ukropec J, Schecter J, Lonial S, Martinez-Lopez J, Mateos MV, Bladé J, Benboubker L, Oriol A, Arnulf B, Rodriguez-Otero P, Moreau P. Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood. 2019 08 01; 134(5):421-431. PMID: 31113777; PMCID: PMC6676132.
      Citations: 56     Fields:    Translation:HumansCTClinical Trials
    66. Kaufman JL, Mina R, Jakubowiak AJ, Zimmerman TL, Wolf JJ, Lewis C, Gleason C, Sharp C, Martin T, Heffner LT, Nooka AK, Harvey RD, Lonial S. Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study. Blood Cancer J. 2019 01 04; 9(1):3. PMID: 30610196; PMCID: PMC6320362.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    67. Ailawadhi S, Panjabi S, Campioni M, Majer I, Jakubowiak A. Reframing the Value of Treatments for Relapsed/Refractory Multiple Myeloma. J Manag Care Spec Pharm. 2018 07; 24(7):711-712. PMID: 29952705; PMCID: PMC10397654.
      Citations:    Fields:    Translation:Humans
    68. Vogl DT, Dingli D, Cornell RF, Huff CA, Jagannath S, Bhutani D, Zonder J, Baz R, Nooka A, Richter J, Cole C, Vij R, Jakubowiak A, Abonour R, Schiller G, Parker TL, Costa LJ, Kaminetzky D, Hoffman JE, Yee AJ, Chari A, Siegel D, Fonseca R, Van Wier S, Ahmann G, Lopez I, Kauffman M, Shacham S, Saint-Martin JR, Picklesimer CD, Choe-Juliak C, Stewart AK. Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma. J Clin Oncol. 2018 03 20; 36(9):859-866. PMID: 29381435; PMCID: PMC6905485.
      Citations: 67     Fields:    Translation:HumansCTClinical Trials
    69. Siegel DS, Dimopoulos MA, Ludwig H, Facon T, Goldschmidt H, Jakubowiak A, San-Miguel J, Obreja M, Blaedel J, Stewart AK. Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. J Clin Oncol. 2018 03 10; 36(8):728-734. PMID: 29341834.
      Citations: 107     Fields:    Translation:Humans
    70. ALCYONE Trial Investigators, Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Kaplan P, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Iosava G, Fujisaki T, Garg M, Chiu C, Wang J, Carson R, Crist W, Deraedt W, Nguyen H, Qi M, San-Miguel J. Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. N Engl J Med. 2018 02 08; 378(6):518-528. PMID: 29231133.
      Citations: 365     Fields:    Translation:HumansCTClinical Trials
    71. Jakubowiak AJ, Houisse I, Campioni M, Panjabi S, Ailawadhi S, Májer I, Benedict Á. Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States. Expert Rev Hematol. 2017 12; 10(12):1107-1119. PMID: 29027825.
      Citations: 8     Fields:    Translation:Humans
    72. van Beers EH, van Vliet MH, Kuiper R, de Best L, Anderson KC, Chari A, Jagannath S, Jakubowiak A, Kumar SK, Levy JB, Auclair D, Lonial S, Reece D, Richardson P, Siegel DS, Stewart AK, Trudel S, Vij R, Zimmerman TM, Fonseca R. Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2017 09; 17(9):555-562. PMID: 28735890.
      Citations: 17     Fields:    Translation:Humans
    73. Thompson RM, Dytfeld D, Reyes L, Robinson RM, Smith B, Manevich Y, Jakubowiak A, Komarnicki M, Przybylowicz-Chalecka A, Szczepaniak T, Mitra AK, Van Ness BG, Luczak M, Dolloff NG. Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells. Oncotarget. 2017 May 30; 8(22):35863-35876. PMID: 28415782; PMCID: PMC5482623.
      Citations: 63     Fields:    Translation:HumansCells
    74. Jakubowiak AJ, DeCara JM, Mezzi K. Cardiovascular events during carfilzomib therapy for relapsed myeloma: practical management aspects from two case studies. Hematology. 2017 Dec; 22(10):585-591. PMID: 28545322.
      Citations: 10     Fields:    Translation:Humans
    75. Luczak M, Kubicki T, Rzetelska Z, Szczepaniak T, Przybylowicz-Chalecka A, Ratajczak B, Czerwinska-Rybak J, Nowicki A, Joks M, Jakubowiak A, Komarnicki M, Dytfeld D. Comparative proteomic profiling of sera from patients with refractory multiple myeloma reveals potential biomarkers predicting response to bortezomib-based therapy. Pol Arch Intern Med. 2017 06 30; 127(6):392-400. PMID: 28546528.
      Citations: 9     Fields:    Translation:Humans
    76. Dimopoulos MA, Stewart AK, Siegel D, Mihaylov GG, Goranova-Marinova V, Suvorov A, Niesvizky R, Jakubowiak A, Ludwig H, Ro S, Aggarwal S, Moreau P, Palumbo A, Masszi T, Špicka I, Oriol A, Hájek R, Rosiñol L, Rajnics P, San-Miguel J. Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment. Blood Cancer J. 2017 04 21; 7(4):e554. PMID: 28430175; PMCID: PMC5436074.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    77. Dimopoulos MA, Stewart AK, Siegel D, Mihaylov GG, Goranova-Marinova V, Suvorov A, Niesvizky R, Jakubowiak A, San-Miguel J, Ludwig H, Palumbo A, Obreja M, Aggarwal S, Moreau P, Masszi T, Špicka I, Oriol A, Hájek R, Rosiñol L, Rajnics P. Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study. Br J Haematol. 2017 05; 177(3):404-413. PMID: 28211560; PMCID: PMC5412871.
      Citations: 29     Fields:    Translation:HumansCTClinical Trials
    78. Stewart AK, Dimopoulos MA, Masszi T, Špicka I, Oriol A, Hájek R, Rosiñol L, Siegel DS, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Buchanan J, Cocks K, Yang X, Xing B, Zojwalla N, Tonda M, Moreau P, Palumbo A. Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma. J Clin Oncol. 2016 11 10; 34(32):3921-3930. PMID: 27601539; PMCID: PMC5791840.
      Citations: 27     Fields:    Translation:HumansCTClinical Trials
    79. Dytfeld D, Luczak M, Wrobel T, Usnarska-Zubkiewicz L, Brzezniakiewicz K, Jamroziak K, Giannopoulos K, Przybylowicz-Chalecka A, Ratajczak B, Czerwinska-Rybak J, Nowicki A, Joks M, Zawartko M, Szczepaniak T, Grzasko N, Morawska M, Bochenek M, Kubicki T, Morawska M, Tusznio K, Jakubowiak A, Czechowska E, Komarnicki MA. Comparative proteomic profiling of refractory/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy. Oncotarget. 2016 Aug 30; 7(35):56726-56736. PMID: 27527861; PMCID: PMC5302948.
      Citations: 35     Fields:    Translation:Humans
    80. Stefka AT, Park JH, Matsuo Y, Chung S, Nakamura Y, Jakubowiak AJ, Rosebeck S. Anti-myeloma activity of MELK inhibitor OTS167: effects on drug-resistant myeloma cells and putative myeloma stem cell replenishment of malignant plasma cells. Blood Cancer J. 2016 08 19; 6(8):e460. PMID: 27540718; PMCID: PMC5022182.
      Citations: 11     Fields:    Translation:HumansCells
    81. Fonseca R, Siegel D, Dimopoulos MA, Goranova-Marinova V, Mihaylov G, Wang M, Niesvizky R, Jakubowiak A, Minarik J, Palumbo A, Bensinger W, Kukreti V, Ben-Yehuda D, Stewart AK, Obreja M, Moreau P, Avet-Loiseau H, Špicka I, Masszi T, Hájek R, Rosiñol L, Maisnar V, Mateos MV, Oriol A. Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. Blood. 2016 09 01; 128(9):1174-80. PMID: 27439911; PMCID: PMC5009511.
      Citations: 47     Fields:    Translation:HumansCTClinical Trials
    82. Chari A, Htut M, Zonder JA, Fay JW, Jakubowiak AJ, Levy JB, Lau K, Burt SM, Tunquist BJ, Hilder BW, Rush SA, Walker DH, Ptaszynski M, Kaufman JL. A phase 1 dose-escalation study of filanesib plus bortezomib and dexamethasone in patients with recurrent/refractory multiple myeloma. Cancer. 2016 Nov 15; 122(21):3327-3335. PMID: 27433944; PMCID: PMC6857452.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    83. Jakubowiak AJ, Campioni M, Houisse I, Tichy E, Giannopoulou A, Aggarwal SK, Barber BL, Panjabi S, Benedict Á. Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective. J Med Econ. 2016 Nov; 19(11):1061-1074. PMID: 27224006.
      Citations: 15     Fields:    Translation:Humans
    84. Jakubowiak A, Offidani M, Laribi K, Bosi A, Marasca R, Laubach J, Mohrbacher A, Carella AM, Singhal AK, Tsao LC, Lynch M, Bleickardt E, Jou YM, Robbins M, Pégourie B, De La Rubia J, Garderet L, Palumbo A. Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM. Blood. 2016 06 09; 127(23):2833-40. PMID: 27091875; PMCID: PMC4900953.
      Citations: 101     Fields:    Translation:HumansCTClinical Trials
    85. Richardson PG, Zimmerman TM, Hofmeister CC, Talpaz M, Chanan-Khan AA, Kaufman JL, Laubach JP, Chauhan D, Jakubowiak AJ, Reich S, Trikha M, Anderson KC. Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1. Blood. 2016 06 02; 127(22):2693-700. PMID: 27009059; PMCID: PMC5413296.
      Citations: 35     Fields:    Translation:HumansCTClinical Trials
    86. Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, Belch A, Krishnan A, Vescio RA, Mazumder A, Orlowski RZ, Sutherland HJ, Scott EC, Berdeja J, Gharibo M, Stevens DA, Sebag M, Callander N, Jakubowiak A, White D, Richardson PG, Lisby S, Feng H, Uhlar CM, Khan I, Ahmadi T, Voorhees PM, Mateos MV, Bladé J, Oriol A, LeBlanc R, de la Rubia J. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016 Apr 09; 387(10027):1551-1560. PMID: 26778538.
      Citations: 342     Fields:    Translation:HumansCTClinical Trials
    87. Rosebeck S, Alonge MM, Kandarpa M, Mayampurath A, Volchenboum SL, Jasielec J, Dytfeld D, Maxwell SP, Kraftson SJ, McCauley D, Shacham S, Kauffman M, Jakubowiak AJ. Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10-Dependent Apoptosis by Carfilzomib and Selinexor. Mol Cancer Ther. 2016 Jan; 15(1):60-71. PMID: 26637366.
      Citations: 27     Fields:    Translation:HumansAnimalsCells
    88. Richardson PG, Jagannath S, Moreau P, Jakubowiak AJ, Raab MS, Vij R, White D, Reece DE, Zonder J, Tsao LC, Anderson KC, Bleickardt E, Singhal AK, Lonial S, 1703 study investigators, Facon T, Benboubker L. Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study. Lancet Haematol. 2015 Dec; 2(12):e516-27. PMID: 26686406; PMCID: PMC6871650.
      Citations: 68     Fields:    Translation:HumansCTClinical Trials
    89. Shah JJ, Jakubowiak AJ, O'Connor OA, Orlowski RZ, Harvey RD, Smith MR, Lebovic D, Diefenbach C, Kelly K, Hua Z, Berger AJ, Mulligan G, Tirrell S, Dezube BJ, Lonial S, Faessel HM. Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma. Clin Cancer Res. 2016 Jan 01; 22(1):34-43. PMID: 26561559; PMCID: PMC5694347.
      Citations: 101     Fields:    Translation:HumansCTClinical Trials
    90. Vij R, Wang M, Jagannath S, Niesvizky R, Jakubowiak AJ, Kavalerchik E, Huang M, Siegel DS. Serum free light chain reduction correlates with response and progression-free survival following carfilzomib therapy in relapsed/refractory multiple myeloma. Leuk Lymphoma. 2015; 56(10):2959-61. PMID: 25699653.
      Citations: 2     Fields:    Translation:Humans
    91. Dytfeld D, Rosebeck S, Kandarpa M, Mayampurath A, Mellacheruvu D, Alonge MM, Ngoka L, Jasielec J, Richardson PG, Volchenboum S, Nesvizhskii AI, Sreekumar A, Jakubowiak AJ. Proteomic profiling of naïve multiple myeloma patient plasma cells identifies pathways associated with favourable response to bortezomib-based treatment regimens. Br J Haematol. 2015 Jul; 170(1):66-79. PMID: 25824111.
      Citations: 12     Fields:    Translation:HumansCellsCTClinical Trials
    92. Peterson LF, Sun H, Liu Y, Potu H, Kandarpa M, Ermann M, Courtney SM, Young M, Showalter HD, Sun D, Jakubowiak A, Malek SN, Talpaz M, Donato NJ. Targeting deubiquitinase activity with a novel small-molecule inhibitor as therapy for B-cell malignancies. Blood. 2015 Jun 04; 125(23):3588-97. PMID: 25814533.
      Citations: 63     Fields:    Translation:HumansAnimalsCells
    93. Stewart AK, Rajkumar SV, Dimopoulos MA, Oriol A, Siegel DS, Mihaylov GG, Goranova-Marinova V, Suvorov A, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Wang M, Minarik J, Bensinger WI, Mateos MV, Ben-Yehuda D, Kukreti V, Zojwalla N, Tonda ME, Yang X, Xing B, Moreau P, Palumbo A, ASPIRE Investigators, Masszi T, Špicka I, Hájek R, Rosiñol L, Rajnics P, Maisnar V. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015 Jan 08; 372(2):142-52. PMID: 25482145.
      Citations: 534     Fields:    Translation:Humans
    94. Dytfeld D, Jasielec J, Griffith KA, Lebovic D, Vesole DH, Jagannath S, Al-Zoubi A, Anderson T, Detweiler-Short K, Stockerl-Goldstein K, Ahmed A, Jobkar T, Durecki DE, McDonnell K, Mietzel M, Couriel D, Kaminski M, Vij R, Jakubowiak AJ. Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma. Haematologica. 2014 Sep; 99(9):e162-4. PMID: 24972772; PMCID: PMC4562550.
      Citations: 17     Fields:    Translation:Humans
    95. Richardson PG, Baz R, Wang M, Jakubowiak AJ, Laubach JP, Harvey RD, Talpaz M, Berg D, Liu G, Yu J, Gupta N, Di Bacco A, Hui AM, Lonial S. Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. Blood. 2014 Aug 14; 124(7):1038-46. PMID: 24920586; PMCID: PMC4574453.
      Citations: 91     Fields:    Translation:HumansCTClinical Trials
    96. Jakubowiak AJ. Evolution of carfilzomib dose and schedule in patients with multiple myeloma: a historical overview. Cancer Treat Rev. 2014 Jul; 40(6):781-90. PMID: 24630735.
      Citations: 24     Fields:    Translation:HumansAnimals
    97. Laubach JP, Voorhees PM, Hassoun H, Jakubowiak A, Lonial S, Richardson PG. Current strategies for treatment of relapsed/refractory multiple myeloma. Expert Rev Hematol. 2014 Feb; 7(1):97-111. PMID: 24471924.
      Citations: 29     Fields:    Translation:Humans
    98. Richardson PG, Xie W, Jagannath S, Jakubowiak A, Lonial S, Raje NS, Alsina M, Ghobrial IM, Schlossman RL, Munshi NC, Mazumder A, Vesole DH, Kaufman JL, Colson K, McKenney M, Lunde LE, Feather J, Maglio ME, Warren D, Francis D, Hideshima T, Knight R, Esseltine DL, Mitsiades CS, Weller E, Anderson KC. A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood. 2014 Mar 06; 123(10):1461-9. PMID: 24429336; PMCID: PMC4123434.
      Citations: 78     Fields:    Translation:HumansCTClinical Trials
    99. Richardson PG, Siegel DS, Vij R, Hofmeister CC, Baz R, Jagannath S, Chen C, Lonial S, Jakubowiak A, Bahlis N, Song K, Belch A, Raje N, Shustik C, Lentzsch S, Lacy M, Mikhael J, Matous J, Vesole D, Chen M, Zaki MH, Jacques C, Yu Z, Anderson KC. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. 2014 Mar 20; 123(12):1826-32. PMID: 24421329; PMCID: PMC3962162.
      Citations: 143     Fields:    Translation:HumansCTClinical Trials
    100. Jakubowiak AJ. Introduction: recent advances in the understanding and management of multiple myeloma. Semin Oncol. 2013 Oct; 40(5):535-6. PMID: 24135397.
      Citations: 1     Fields:    Translation:Humans
    101. Rosenbaum C, Jasielec J, Laubach J, Paba Prada C, Richardson P, Jakubowiak AJ. Evolving strategies in the initial treatment of multiple myeloma. Semin Oncol. 2013 Oct; 40(5):592-601. PMID: 24135404.
      Citations: 2     Fields:    Translation:Humans
    102. Jakubowiak AJ, Siegel DS, Martin T, Wang M, Vij R, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Harrison BL, Wong AF, Orlowski RZ, Jagannath S. Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study. Leukemia. 2013 Dec; 27(12):2351-6. PMID: 23670297; PMCID: PMC3865533.
      Citations: 39     Fields:    Translation:HumansCTClinical Trials
    103. Jasielec JK, Jakubowiak AJ. Current approaches to the initial treatment of symptomatic multiple myeloma. Int J Hematol Oncol. 2013 Feb; 2(1). PMID: 24286003; PMCID: PMC3839860.
      Citations: 5     
    104. Jagannath S, Vij R, Stewart AK, Trudel S, Jakubowiak AJ, Reiman T, Somlo G, Bahlis N, Lonial S, Kunkel LA, Wong A, Orlowski RZ, Siegel DS. An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2012 Oct; 12(5):310-8. PMID: 23040437.
      Citations: 49     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    105. Vij R, Siegel DS, Jagannath S, Jakubowiak AJ, Stewart AK, McDonagh K, Bahlis N, Belch A, Kunkel LA, Wear S, Wong AF, Wang M. An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol. 2012 Sep; 158(6):739-48. PMID: 22845873; PMCID: PMC5818209.
      Citations: 77     Fields:    Translation:HumansCTClinical Trials
    106. Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Kunkel L, Wear S, Wong AF, Orlowski RZ, Jagannath S. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012 Oct 04; 120(14):2817-25. PMID: 22833546; PMCID: PMC4123387.
      Citations: 264     Fields:    Translation:HumansCTClinical Trials
    107. Jakubowiak A. Management strategies for relapsed/refractory multiple myeloma: current clinical perspectives. Semin Hematol. 2012 Jul; 49 Suppl 1:S16-32. PMID: 22727389.
      Citations: 15     Fields:    Translation:Humans
    108. Jakubowiak A. Novel therapies for relapsed/refractory multiple myeloma: how can we improve on "salvage" therapy?--introduction. Semin Hematol. 2012 Jul; 49 Suppl 1:S1-2. PMID: 22727388.
      Citations: 2     Fields:    Translation:Humans
    109. Jakubowiak AJ, Dytfeld D, Griffith KA, Lebovic D, Vesole DH, Jagannath S, Al-Zoubi A, Anderson T, Nordgren B, Detweiler-Short K, Stockerl-Goldstein K, Ahmed A, Jobkar T, Durecki DE, McDonnell K, Mietzel M, Couriel D, Kaminski M, Vij R. A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood. 2012 Aug 30; 120(9):1801-9. PMID: 22665938; PMCID: PMC5162553.
      Citations: 168     Fields:    Translation:HumansCTClinical Trials
    110. Jakubowiak AJ, Richardson PG, Zimmerman T, Alsina M, Kaufman JL, Kandarpa M, Kraftson S, Ross CW, Harvey C, Hideshima T, Sportelli P, Poradosu E, Gardner L, Giusti K, Anderson KC. Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study. Br J Haematol. 2012 Aug; 158(4):472-80. PMID: 22640031.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    111. Vij R, Wang M, Kaufman JL, Lonial S, Jakubowiak AJ, Stewart AK, Kukreti V, Jagannath S, McDonagh KT, Alsina M, Bahlis NJ, Reu FJ, Gabrail NY, Belch A, Matous JV, Lee P, Rosen P, Sebag M, Vesole DH, Kunkel LA, Wear SM, Wong AF, Orlowski RZ, Siegel DS. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood. 2012 Jun 14; 119(24):5661-70. PMID: 22555973; PMCID: PMC4123327.
      Citations: 105     Fields:    Translation:HumansCTClinical Trials
    112. Jakubowiak AJ, Benson DM, Bensinger W, Siegel DS, Zimmerman TM, Mohrbacher A, Richardson PG, Afar DE, Singhal AK, Anderson KC. Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. J Clin Oncol. 2012 Jun 01; 30(16):1960-5. PMID: 22291084; PMCID: PMC4874204.
      Citations: 69     Fields:    Translation:HumansCTClinical Trials
    113. Richardson PG, Wolf J, Jakubowiak A, Zonder J, Lonial S, Irwin D, Densmore J, Krishnan A, Raje N, Bar M, Martin T, Schlossman R, Ghobrial IM, Munshi N, Laubach J, Allerton J, Hideshima T, Colson K, Poradosu E, Gardner L, Sportelli P, Anderson KC. Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. J Clin Oncol. 2011 Nov 10; 29(32):4243-9. PMID: 21990396.
      Citations: 46     Fields:    Translation:HumansCTClinical Trials
    114. Richardson PG, Lonial S, Jakubowiak AJ, Harousseau JL, Anderson KC. Monoclonal antibodies in the treatment of multiple myeloma. Br J Haematol. 2011 Sep; 154(6):745-54. PMID: 21777223.
      Citations: 34     Fields:    Translation:Humans
    115. Dytfeld D, Griffith KA, Friedman J, Lebovic D, Harvey C, Kaminski MS, Jakubowiak AJ. Superior overall survival of patients with myeloma achieving very good partial response or better to initial treatment with bortezomib, pegylated liposomal doxorubicin, and dexamethasone, predicted after two cycles by a free light chain- and M-protein-based model: extended follow-up of a phase II trial. Leuk Lymphoma. 2011 Jul; 52(7):1271-80. PMID: 21699382.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    116. Zangari M, Aujay M, Zhan F, Hetherington KL, Berno T, Vij R, Jagannath S, Siegel D, Keith Stewart A, Wang L, Orlowski RZ, Belch A, Jakubowiak A, Somlo G, Trudel S, Bahlis N, Lonial S, Singhal S, Kukreti V, Tricot G. Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients. Eur J Haematol. 2011 Jun; 86(6):484-7. PMID: 21477075.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    117. Jakubowiak AJ, Griffith KA, Reece DE, Hofmeister CC, Lonial S, Zimmerman TM, Campagnaro EL, Schlossman RL, Laubach JP, Raje NS, Anderson T, Mietzel MA, Harvey CK, Wear SM, Barrickman JC, Tendler CL, Esseltine DL, Kelley SL, Kaminski MS, Anderson KC, Richardson PG. Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial. Blood. 2011 Jul 21; 118(3):535-43. PMID: 21596852; PMCID: PMC3142898.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    118. Siegel DS, Vij R, Jakubowiak AJ. Clinical roundtable monograph. Emerging treatment options for relapsed and refractory multiple myeloma. Clin Adv Hematol Oncol. 2011 Apr; 9(4):1-15. PMID: 21928467.
      Citations: 2     Fields:    Translation:Humans
    119. Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, Harview CL, Brunet JP, Ahmann GJ, Adli M, Anderson KC, Ardlie KG, Auclair D, Baker A, Bergsagel PL, Bernstein BE, Drier Y, Fonseca R, Gabriel SB, Hofmeister CC, Jagannath S, Jakubowiak AJ, Krishnan A, Levy J, Liefeld T, Lonial S, Mahan S, Mfuko B, Monti S, Perkins LM, Onofrio R, Pugh TJ, Rajkumar SV, Ramos AH, Siegel DS, Sivachenko A, Stewart AK, Trudel S, Vij R, Voet D, Winckler W, Zimmerman T, Carpten J, Trent J, Hahn WC, Garraway LA, Meyerson M, Lander ES, Getz G, Golub TR. Initial genome sequencing and analysis of multiple myeloma. Nature. 2011 Mar 24; 471(7339):467-72. PMID: 21430775; PMCID: PMC3560292.
      Citations: 784     Fields:    Translation:HumansCells
    120. Ghobrial IM, Weller E, Vij R, Munshi NC, Banwait R, Bagshaw M, Schlossman R, Leduc R, Chuma S, Kunsman J, Laubach J, Jakubowiak AJ, Maiso P, Roccaro A, Armand P, Dollard A, Warren D, Harris B, Poon T, Sam A, Rodig S, Anderson KC, Richardson PG. Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study. Lancet Oncol. 2011 Mar; 12(3):263-72. PMID: 21345726.
      Citations: 34     Fields:    Translation:HumansCTClinical Trials
    121. Cavaletti G, Jakubowiak AJ. Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies. Leuk Lymphoma. 2010 Jul; 51(7):1178-87. PMID: 20497001.
      Citations: 50     Fields:    Translation:Humans
    122. Richardson PG, Weller E, Lonial S, Jakubowiak AJ, Jagannath S, Raje NS, Avigan DE, Xie W, Ghobrial IM, Schlossman RL, Mazumder A, Munshi NC, Vesole DH, Joyce R, Kaufman JL, Doss D, Warren DL, Lunde LE, Kaster S, Delaney C, Hideshima T, Mitsiades CS, Knight R, Esseltine DL, Anderson KC. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010 Aug 05; 116(5):679-86. PMID: 20385792; PMCID: PMC3324254.
      Citations: 319     Fields:    Translation:CTClinical Trials
    123. Fonseca R, Richardson P, Giralt S, Lonial S, Rajkumar SV, Stewart AK, Bensinger W, Somlo G, Vescio R, Mikhael J, Reeder C, Tiedemann R, Tricot G, Rifkin R, Shaughnessy J, Munshi N, Raje N, Ghobrial I, Laubach J, Schlossman R, Treon S, Mahindra A, Avigan D, Rosenblatt J, Jagannath S, Niesvizky R, Landau H, Chen-Kiang S, Siegel DS, Zimmerman T, Mehta J, Vesole D, Rosen S, Hofmeister C, Lacy M, Dispenzieri A, Borrello I, Hayman SR, Kumar S, Buadi F, Dingli D, Russell S, Melissa Alsina MA, Fernandez H, Roy V, Pereira D, Stadtmauer E, Vij R, Jakubowiak A, Lentzsch S, Song K, Trudel S, Chen C, Reece D, Stewart D, Singhal S, Comenzo R, Gertz MA, Greipp PR, Durie B, Barlogie B, Anderson K, Dalton W, Coleman M, Novis S, Kyle RA. Conflicts of interest, authorship, and disclosures in industry-related scientific publications. Mayo Clin Proc. 2010 Feb; 85(2):197-9; author reply 201-4. PMID: 20118399; PMCID: PMC2813833.
      Citations:    Fields:    Translation:Humans
    124. Jakubowiak AJ, Kendall T, Al-Zoubi A, Khaled Y, Mineishi S, Ahmed A, Campagnaro E, Brozo C, Braun T, Talpaz M, Kaminski MS. Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma. J Clin Oncol. 2009 Oct 20; 27(30):5015-22. PMID: 19738129.
      Citations: 27     Fields:    Translation:HumansCTClinical Trials
    125. Hussein MA, Bolejack V, Zonder JA, Durie BG, Jakubowiak AJ, Crowley JJ, Barlogie B. Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-plus-prednisone maintenance for untreated multiple myeloma: a southwest oncology group trial (S0204). J Clin Oncol. 2009 Jul 20; 27(21):3510-7. PMID: 19546405; PMCID: PMC2717757.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    126. Lonial S, Richardson PG, Sonneveld P, Schuster MW, Cavenagh J, Rajkumar SV, Jakubowiak AJ, Esseltine DL, Anderson KC, Harousseau JL, San Miguel J, Bladé J. Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma. Br J Haematol. 2008 Oct; 143(2):222-9. PMID: 18713253.
      Citations: 27     Fields:    Translation:Humans
    127. Richardson PG, San-Miguel J, Lonial S, Reece D, Jakubowiak A, Hussein M, Jagannath S, Mitsiades CS, Raje N, Kaufman J, Avigan D, Ghobrial I, Schlossman RL, Munshi N, Dalton W, Anderson KC. The research mission in myeloma. Leukemia. 2009 Feb; 23(2):422-3; author reply 423-4. PMID: 18685616.
      Citations:    Fields:    Translation:Humans
    128. Richardson PG, Lonial S, Jakubowiak A, Jagannath S, Raje N, Avigan D, Ghobrial IM, Knight R, Esseltine D, Anderson KC. Safety and efficacy of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with newly diagnosed multiple myeloma (MM): A phase I/II study. J Clin Oncol. 2008 May 20; 26(15_suppl):8520. PMID: 27951178.
      Citations:    
    129. Anderson KC, Jagannath S, Jakubowiak A, Lonial S, Raje N, Schlossman R, Munshi N, Knight R, Esseltine D, Richardson PG. Phase II study of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with relapsed or relapsed and refractory multiple myeloma (MM). J Clin Oncol. 2008 May 20; 26(15_suppl):8545. PMID: 27951230.
      Citations:    
    130. Kujawski L, Ouillette P, Erba H, Saddler C, Jakubowiak A, Kaminski M, Shedden K, Malek SN. Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia. Blood. 2008 Sep 01; 112(5):1993-2003. PMID: 18436738; PMCID: PMC2518900.
      Citations: 30     Fields:    Translation:HumansCells
    131. Nikiforov MA, Riblett M, Tang WH, Gratchouck V, Zhuang D, Fernandez Y, Verhaegen M, Varambally S, Chinnaiyan AM, Jakubowiak AJ, Soengas MS. Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition. Proc Natl Acad Sci U S A. 2007 Dec 04; 104(49):19488-93. PMID: 18042711; PMCID: PMC2148316.
      Citations: 97     Fields:    Translation:HumansCells
    132. Stadtmauer EA, Lonial S, Vesole DH, Abonour R, Alsina M, Badros A, Comenzo R, Durie B, Giralt S, Hussein M, Jakubowiak A, Mehta J, Niesvizky R, Orlowski R, Siegel D, Singhal S, Vescio R, Wang M, Zangari M, Munshi NC. A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings. Clin Adv Hematol Oncol. 2007 Oct; 5(10 Suppl 15):7-19, quiz 21-2. PMID: 18000495.
      Citations: 1     Fields:    Translation:Humans
    133. Richardson PG, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Miguel JS, Boccadoro M, Cavenagh J, Alsina M, Rajkumar SV, Lacy M, Jakubowiak A, Dalton W, Boral A, Esseltine DL, Schenkein D, Anderson KC, Bladé J. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood. 2007 Nov 15; 110(10):3557-60. PMID: 17690257.
      Citations: 164     Fields:    Translation:HumansCTClinical Trials
    134. Golde DW, Jakubowiak A, Caggiano J, Heaney ML. Cladribine underdosing in hairy-cell leukemia: a cause for apparent response failure. Leuk Lymphoma. 2002 Feb; 43(2):365-7. PMID: 11999571.
      Citations:    Fields:    Translation:Humans
    135. Jakubowiak A, Pouponnot C, Berguido F, Frank R, Mao S, Massague J, Nimer SD. Inhibition of the transforming growth factor beta 1 signaling pathway by the AML1/ETO leukemia-associated fusion protein. J Biol Chem. 2000 Dec 22; 275(51):40282-7. PMID: 11032826.
      Citations: 30     Fields:    Translation:AnimalsCells
    136. Jakubowiak A, Cammenga J, Sokolic R, Alvarez S, Jackson G, Hedvat C, Nimer SD. Molecular biology of leukemia. Curr Oncol Rep. 2000 Mar; 2(2):123-31. PMID: 11122833.
      Citations:    Fields:    Translation:Humans
    137. Frank RC, Sun X, Berguido FJ, Jakubowiak A, Nimer SD. The t(8;21) fusion protein, AML1/ETO, transforms NIH3T3 cells and activates AP-1. Oncogene. 1999 Mar 04; 18(9):1701-10. PMID: 10208431.
      Citations: 17     Fields:    Translation:HumansAnimalsCells
    138. Kaiser UB, Jakubowiak A, Steinberger A, Chin WW. Differential effects of gonadotropin-releasing hormone (GnRH) pulse frequency on gonadotropin subunit and GnRH receptor messenger ribonucleic acid levels in vitro. Endocrinology. 1997 Mar; 138(3):1224-31. PMID: 9048630.
      Citations: 70     Fields:    Translation:AnimalsCells
    139. Kaiser UB, Jakubowiak A, Steinberger A, Chin WW. Regulation of rat pituitary gonadotropin-releasing hormone receptor mRNA levels in vivo and in vitro. Endocrinology. 1993 Aug; 133(2):931-4. PMID: 8393779.
      Citations: 48     Fields:    Translation:AnimalsCells
    140. Janecki A, Jakubowiak A, Steinberger A. Effect of cadmium chloride on transepithelial electrical resistance of Sertoli cell monolayers in two-compartment cultures--a new model for toxicological investigations of the "blood-testis" barrier in vitro. Toxicol Appl Pharmacol. 1992 Jan; 112(1):51-7. PMID: 1733048.
      Citations: 55     Fields:    Translation:AnimalsCells
    141. Jakubowiak A, Janecki A, Tong D, Sanborn BM, Steinberger A. Effects of recombinant human inhibin and testosterone on gonadotropin secretion and subunit mRNA in superfused male rat pituitary cell cultures stimulated with pulsatile gonadotropin-releasing hormone. Mol Cell Endocrinol. 1991 Dec; 82(2-3):265-73. PMID: 1794614.
      Citations:    Fields:    Translation:HumansAnimalsCells
    142. Janecki A, Jakubowiak A, Steinberger A. Effects of cyclic AMP and phorbol ester on transepithelial electrical resistance of Sertoli cell monolayers in two-compartment culture. Mol Cell Endocrinol. 1991 Nov; 82(1):61-9. PMID: 1722179.
      Citations: 17     Fields:    Translation:AnimalsCells
    143. Janecki A, Jakubowiak A, Steinberger A. Regulation of transepithelial electrical resistance in two-compartment Sertoli cell cultures: in vitro model of the blood-testis barrier. Endocrinology. 1991 Sep; 129(3):1489-96. PMID: 1908377.
      Citations: 33     Fields:    Translation:AnimalsCells
    144. Jakubowiak A, Tong D, Janecki A, Sanborn BM, Steinberger A. Pulsatile GnRH stimulation increases steady-state mRNA levels for FSHbeta, LHbeta, and alpha subunits in superfused pituitary cell cultures. Mol Cell Neurosci. 1991 Aug; 2(4):277-83. PMID: 19912809.
      Citations: 1     Fields:    
    145. Jakubowiak A, Janecki A, Steinberger A. Kinetics of inhibin secretion in static and superfused Sertoli cell cultures in response to follicle-stimulating hormone. Biol Reprod. 1990 Dec; 43(6):939-45. PMID: 2127231.
      Citations:    Fields:    Translation:AnimalsCells
    146. Janecki A, Jakubowiak A, Steinberger A. Vectorial secretion of inhibin by immature rat Sertoli cells in vitro: reexamination of previous results. Endocrinology. 1990 Oct; 127(4):1896-903. PMID: 2169406.
      Citations: 1     Fields:    Translation:AnimalsCells
    147. Jakubowiak A, Janecki A, Steinberger A. Action kinetics of inhibin in superfused pituitary cells depend on gonadotropin-releasing hormone treatment. Endocrinology. 1990 Jul; 127(1):211-7. PMID: 2113866.
      Citations:    Fields:    Translation:AnimalsCells
    148. Jakubowiak A, Janecki A, Steinberger A. Similar effects of inhibin and cycloheximide on gonadotropin release in superfused pituitary cell cultures. Biol Reprod. 1989 Sep; 41(3):454-63. PMID: 2511933.
      Citations: 3     Fields:    Translation:AnimalsCells
    149. Kowalik I, Kurpisz M, Jakubowiak A, Janecki A, Lukaszyk A, Szymczynski G. Evaluation of HLA expression on gametogenic cells isolated from human testis. Andrologia. 1989 May-Jun; 21(3):237-43. PMID: 2774218.
      Citations: 1     Fields:    Translation:HumansCells
    150. Jakubowiak A, Janecki A, Steinberger A. Transferrin secretion in response to different modes of FSH stimulation and cycloheximide in superfused Sertoli cell cultures. J Androl. 1988 Nov-Dec; 9(6):390-6. PMID: 3145931.
      Citations:    Fields:    Translation:AnimalsCells
    151. Janecki A, Jakubowiak A, Steinberger A. Effect of germ cells on vectorial secretion of androgen binding protein and transferrin by immature rat Sertoli cells in vitro. J Androl. 1988 Mar-Apr; 9(2):126-32. PMID: 3133343.
      Citations: 2     Fields:    Translation:AnimalsCells
    152. Janecki A, Jakubowiak A, Steinberger A. Study of the dynamics of Sertoli cell secretions in a new superfusion, two-compartment culture system. In Vitro Cell Dev Biol. 1987 Jul; 23(7):492-500. PMID: 3610946.
      Citations: 2     Fields:    Translation:AnimalsCells
    153. Miskowiak B, Janecki A, Jakubowiak A, Limanowski A. Reproductive functions in the adult male rats after prolonged intraventricular administration of corticotropin-releasing factor (CRF). Exp Clin Endocrinol. 1986 Nov; 88(1):25-30. PMID: 3493166.
      Citations:    Fields:    Translation:Animals
    154. Janecki A, Jakubowiak A, Lukaszyk A. Stimulatory effect of Sertoli cell secretory products on testosterone secretion by purified Leydig cells in primary culture. Mol Cell Endocrinol. 1985 Oct; 42(3):235-43. PMID: 3930311.
      Citations: 1     Fields:    Translation:AnimalsCells
    155. Janecki A, Lukaszyk A, Jakubowiak A. Culture of rat Sertoli cells isolated with a modified procedure. Morphological identification of cell population and cell reactivity. Folia Histochem Cytochem (Krakow). 1981; 19(3):135-42. PMID: 6276274.
      Citations: 2     Fields:    Translation:AnimalsCells
    Jakubowiak's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (437)
    Explore
    _
    Co-Authors (31)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _